Suppr超能文献

The putative mechanisms underlying testosterone and cardiovascular risk.

作者信息

Maganty Avinash, Kovac Jason R, Ramasamy Ranjith

机构信息

Department of Urology, Baylor College of Medicine, Houston, TX, 77030, USA.

出版信息

F1000Res. 2014 Apr 4;3:87. doi: 10.12688/f1000research.3869.1. eCollection 2014.

Abstract

The use of testosterone supplementation therapy (TST) is increasing primarily in men with symptomatic hypogonadism. While TST has been shown to have numerous benefits, as its use increases, the role on cardiovascular health must be explored. Previous evidence showed no adverse cardiovascular risks associated with TST use; however, more recent studies suggest that there may be an associated risk. The exact mechanism by which TST may contribute to cardiovascular risk has not been elucidated. Numerous mechanisms have been proposed which include testosterone's effect on thromboxane A2 receptors, vascular adhesion molecule 1 receptors, erythropoiesis, and obstructive sleep apnea, all of which can ultimately lead to atherogenesis and increased cardiovascular risk.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a281/3999929/2ce3bb1525b8/f1000research-3-4144-g0000.jpg

相似文献

1
The putative mechanisms underlying testosterone and cardiovascular risk.
F1000Res. 2014 Apr 4;3:87. doi: 10.12688/f1000research.3869.1. eCollection 2014.
2
Hypogonadism management and cardiovascular health.
Postgrad Med. 2020 Dec;132(sup4):35-41. doi: 10.1080/00325481.2020.1805917. Epub 2020 Oct 19.
3
Testosterone replacement therapy: who to evaluate, what to use, how to follow, and who is at risk?
Hosp Pract (1995). 2014 Dec;42(5):69-82. doi: 10.3810/hp.2014.12.1160.
4
Hypogonadism and Testosterone Therapy: Associations With Cardiovascular Risk.
Am J Mens Health. 2015 Jul;9(4):340-4. doi: 10.1177/1557988314540933. Epub 2014 Jun 26.
5
Testosterone as a modulator of vascular behavior.
Biol Res Nurs. 2004 Apr;5(4):276-85. doi: 10.1177/1099800403262927.
6
Hepcidin is not essential for mediating testosterone's effects on erythropoiesis.
Andrology. 2020 Jan;8(1):82-90. doi: 10.1111/andr.12622. Epub 2019 Apr 19.
7
Testosterone deficiency and chronic kidney disease.
J Clin Transl Endocrinol. 2024 Aug 14;37:100365. doi: 10.1016/j.jcte.2024.100365. eCollection 2024 Sep.
8
Approach to the patient: Low testosterone concentrations in men with obesity.
J Clin Endocrinol Metab. 2025 Mar 7. doi: 10.1210/clinem/dgaf137.
9
The benefits and risks of testosterone replacement therapy: a review.
Ther Clin Risk Manag. 2009 Jun;5(3):427-48. doi: 10.2147/tcrm.s3025. Epub 2009 Jun 22.
10
A multi-step, dynamic allosteric model of testosterone's binding to sex hormone binding globulin.
Mol Cell Endocrinol. 2015 Jan 5;399:190-200. doi: 10.1016/j.mce.2014.09.001. Epub 2014 Sep 21.

引用本文的文献

2
Low Plasma Testosterone Is Associated With Elevated Cardiovascular Disease Biomarkers.
J Sex Med. 2017 Sep;14(9):1095-1103. doi: 10.1016/j.jsxm.2017.06.015. Epub 2017 Jul 27.

本文引用的文献

2
Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.
PLoS One. 2014 Jan 29;9(1):e85805. doi: 10.1371/journal.pone.0085805. eCollection 2014.
5
Cardiovascular events and intensity of treatment in polycythemia vera.
N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.
7
Testosterone treatment and mortality in men with low testosterone levels.
J Clin Endocrinol Metab. 2012 Jun;97(6):2050-8. doi: 10.1210/jc.2011-2591. Epub 2012 Apr 11.
8
Obstructive sleep apnea: an emerging risk factor for atherosclerosis.
Chest. 2011 Aug;140(2):534-542. doi: 10.1378/chest.10-2223.
9
Adverse events associated with testosterone administration.
N Engl J Med. 2010 Jul 8;363(2):109-22. doi: 10.1056/NEJMoa1000485. Epub 2010 Jun 30.
10
Identification of late-onset hypogonadism in middle-aged and elderly men.
N Engl J Med. 2010 Jul 8;363(2):123-35. doi: 10.1056/NEJMoa0911101. Epub 2010 Jun 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验